Is Alzheimer's Disease a Result of Presynaptic Failure? - Synaptic Dysfunctions Induced by Oligomeric β-Amyloid
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Since Alois Alzheimer first described morphological alterations associated with his patient's dementia more than 100 years ago, Alzheimer's disease (AD) was defined as neurodegenerative disease caused by extracellular deposits of misfolded proteins. These amyloid plaques and neurofibrillary tangles have been unambiguously considered as hallmarks of this ailment, accompanied by devastating brain atrophy and cell loss. When a 40-42 amino acid peptide, called beta-amyloid (Abeta), was identified as a main component of amyloid plaques and a few genetic cases of AD were linked to Abeta metabolism, the Abeta hypothesis of AD was proposed. It was initially thought that an increase in Abeta42 precipitates plaque formation, which causes the generation of neurofibrillary tangles and ultimately the death of neurons. However, during the last decade it became apparent that soluble rather than deposited Abeta is associated with dementia. Among the constituents of soluble Abeta, small oligomeric forms were increasingly associated with neuropathology. There is now ample evidence that Abeta oligomers do not affect neuronal viability in general, but interfere specifically with synaptic function. Long-term neurophysiological impairment ultimately causes degeneration of synapses, which becomes most apparent on the morphological level by retraction of dendritic spines. Loss of meaningful synaptic connections in the brain of patients with AD will shatter their capacity to encode and retrieve memories. The precise molecular mechanism of Abeta oligomer-induced impairment of synaptic transmission is not fully understood, but there are several independent observations that oligomers interfere with the vesicular release machinery at the presynaptic terminal. While this hypothesis offers a promising avenue to understand the underlying cause of cognition and memory deficits in the AD brain, it also opens a possibility to address new mechanisms for preventing and ultimately curing AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Cited by
Basic mechanisms of neurodegeneration: a critical update
Jellinger, K. A. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01010.x · Cited by 596
Agholme, L., Lindström, T., Kågedal, K., Marcusson, J., & Hallbeck, M. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091363 · Cited by 498
Targeting p38 MAPK pathway for the treatment of Alzheimer's disease
Munoz, L., & Ammit, A. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.11.010 · Cited by 369
Zhao, J., O'Connor, T., & Vassar, R. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-150 · Cited by 369
Synaptic changes in Alzheimer’s disease and its models
Pozueta, J., Lefort, R., & Shelanski, M. L. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.05.050 · Cited by 307
Metadata
- Authors
- Nimmrich, V., & Ebert, U.
- Venue
- Reviews in the Neurosciences
- Publisher
- Walter de Gruyter GmbH
- Published
- 2009-01
- Volume
- 20
- Issue
- 1
- Pages
- 1-12
- ISSN
- 0334-1763 (ISSN-L)
- 2191-0200
- OpenAlex
- W2014483271
- Cited by
- 139
- References
- 26
- FWCI
- 8.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is Alzheimer's Disease a Result of Presynaptic Failure? - Synaptic Dysfunctions Induced by Oligomeric β-Amyloid. https://app.cochat.ai/papers/10.1515/revneuro.2009.20.1.1
- The paper
- Nimmrich, V., & Ebert, U. (2009). Is Alzheimer's Disease a Result of Presynaptic Failure? - Synaptic Dysfunctions Induced by Oligomeric β-Amyloid. Reviews in the Neurosciences. https://doi.org/10.1515/revneuro.2009.20.1.1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.